Cargando…
Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients
We evaluated a neutralizing anti-TGFβ antibody (GC1008) in cancer patients with malignant pleura mesothelioma (MPM). The goal of this study was to assess immunoregulatory effects in relation to clinical safety and clinical response. Patients with progressive MPM and 1–2 prior systemic therapies rece...
Autores principales: | Stevenson, James P, Kindler, Hedy L, Papasavvas, Emmanouil, Sun, Jing, Jacobs-Small, Mona, Hull, Jennifer, Schwed, Daniel, Ranganathan, Anjana, Newick, Kheng, Heitjan, Daniel F, Langer, Corey J, McPherson, John M, Montaner, Luis J, Albelda, Steven M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3812201/ https://www.ncbi.nlm.nih.gov/pubmed/24179709 http://dx.doi.org/10.4161/onci.26218 |
Ejemplares similares
-
Chimeric antigen receptor T-cell therapy for solid tumors
por: Newick, Kheng, et al.
Publicado: (2016) -
Systemic Treatments for Mesothelioma: Standard and Novel
por: Kindler, Hedy Lee
Publicado: (2008) -
Tumor volume is an independent predictor of survival in patients with malignant pleural mesothelioma
por: Kircheva, Diana Y, et al.
Publicado: (2015) -
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma
por: Kanteti, Rajani, et al.
Publicado: (2016) -
Peroxiredoxin 3 Is a Redox-Dependent Target of Thiostrepton in Malignant Mesothelioma Cells
por: Newick, Kheng, et al.
Publicado: (2012)